J Appl Biomed 16:214-220, 2018 | DOI: 10.1016/j.jab.2018.01.001

Quantification of uPA in breast tumour tissue extracts by microarray immunoassay: Comparison with ELISA technology

Liu Shia, Thomas Gehina, Yann Chevolota, William Jacotb, Pierre-Jean Lamyc,d, Emmanuelle Laurenceaua,*
a Lyon University, Lyon Institute of Nanotechnology INL-UMR5270, CNRS, Ecole Centrale de Lyon, Ecully, France
b Montpellier Cancer Institute Val d'Aurelle, Medical Oncoly Department, Montpellier, France
c Institut Médical d'Analyse Génomique-Labosud, Montpellier, France
d Montpellier Cancer Institute Val d'Aurelle, Translational research unit and Biological Ressources Center, Montpellier, France

The urokinase-type plasminogen activator (uPA) and PA inhibitor 1 (PAI-1) play important roles in breast cancer metastasis through cell migration and invasion. They are clinically applicable prognostic and predictive markers. High levels of uPA and PAI-1 are associated with high risk of recurrence and adjuvant chemotherapy provides substantial benefit for this breast cancer population. The current sole validated method for quantifying uPA level in breast tumour tissue is ELISA assay. It requires 50-300 mg of fresh or frozen tissue, which is the main limitation for routine use. In this study, we evaluated the performances of customized antibody microarray to quantify uPA concentration from reduced extraction solution of breast tumour tissue and compared it with standard ELISA kit. We firstly optimized the elaboration of customized antibody microarray in order to sensitively detect and quantify uPA standard solutions. In the best conditions, we analysed uPA concentration in 16 cytosolic extracts from breast tumour tissue. Results showed that our customized antibody microarray could correctly quantify uPA concentration while consuming 100 times less volume of tumour tissue extraction solution than ELISA. Our antibody microarray is a powerful and promising tool for the miniaturization of the immunoassay quantification of uPA from breast tumour tissue extracts.

Keywords: Breast cancer; uPA quantification; Nano level techniques; Immunological approaches; Antibody microarray

Received: August 3, 2017; Revised: November 17, 2017; Accepted: January 11, 2018; Published: August 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Shi L, Gehin T, Chevolot Y, Jacot W, Lamy P, Laurenceau E. Quantification of uPA in breast tumour tissue extracts by microarray immunoassay: Comparison with ELISA technology. J Appl Biomed. 2018;16(3):214-220. doi: 10.1016/j.jab.2018.01.001.
Download citation

References

  1. Balboni, I., Limb, C., Tenenbaum, J.D., Utz, P.J., 2008. Evaluation of microarray surfaces and arraying parameters for autoantibody profiling. Proteom 8, 3443- 3449. Go to original source... Go to PubMed...
  2. Becker, K.F., Schott, C., Hipp, S., Metzger, V., Porschewski, P., Beck, R., et al., 2007. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol. 211, 370-378. Go to original source... Go to PubMed...
  3. Cretich, M., Damin, F., Chiari, M., 2014. Protein microarray technology: how far off is routine diagnostics? Analyst 139, 528-542. Go to original source... Go to PubMed...
  4. Duffy, M.J., McGowan, P.M., Harbeck, N., Thomssen, C., Schmitt, M., 2014. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-ofevidence-1 studies. Breast Cancer Res. 16, 428. Go to original source... Go to PubMed...
  5. Harbeck, N., Kates, R.E., Look, M.P., Meijer-Van Gelder, M.E., Klijn, J.G., Kruger, A., et al., 2002. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 62, 4617-4622.
  6. Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., et al., 2013. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer 49, 1825-1835. Go to original source... Go to PubMed...
  7. Harris, L.N., Ismaila, N., McShane, L.M., Andre, F., Collyar, D.E., Gonzalez-Angulo, A. M., et al., 2016. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 34, 1134-1150. Go to original source... Go to PubMed...
  8. Hu, S., Xie, Z., Qian, J., Blackshaw, S., Zhu, H., 2012. Functional protein microarray technology. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 255-268. Go to original source... Go to PubMed...
  9. Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., et al., 2001. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93, 913-920. Go to original source... Go to PubMed...
  10. Kwaan, H.C., Mazar, A.P., McMahon, B.J., 2013. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin. Thromb. Hemost. 39, 382-391. Go to original source... Go to PubMed...
  11. Look, M.P., van Putten, W.L., Duffy, M.J., Harbeck, N., Christensen, I.J., Thomssen, C., et al., 2002. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94, 116-128. Go to original source... Go to PubMed...
  12. Malinowsky, K., Bollner, C., Hipp, S., Berg, D., Schmitt, M., Becker, K.F., 2010. UPA and PAI-1 analysis from fixed tissues Ànew perspectives for a known set of predictive markers. Curr. Med. Chem. 17, 4370-4377. Go to original source... Go to PubMed...
  13. Mazurczyk, R., El Khoury, G., Dugas, V., Hannes, B., Laurenceau, E., Cabrera, M., Chevolot, Y., 2008. Low-cost, fast prototyping method of fabrication of the microreactor devices in soda-lime glass. Sens. Actuators B: Chem. 128, 552-559. Go to original source...
  14. McMahon, B., Kwaan, H.C., 2008. The plasminogen activator system and cancer. Pathophysiol. Haemost. Thromb. 36, 184-194. Go to original source... Go to PubMed...
  15. Schueller, G., Jaromi, S., Ponhold, L., Fuchsjaeger, M., Memarsadeghi, M., Rudas, M., et al., 2008. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology 248, 406-413. Go to original source... Go to PubMed...
  16. Shukla, S., Govekar, R.B., Sirdeshmukh, R., Sundaram, C.S., D'Cruz, A.K., Pathak, K.A., et al., 2007. Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex. Proteom. Clin. Appl. 1, 1592-1604. Go to original source... Go to PubMed...
  17. Sutandy, F.X., Qian, J., Chen, C.S., Zhu, H., 2013. Overview of protein microarrays. Curr. Protoc. Protein Sci. (Chapter 27, Unit 27.1.). Go to original source... Go to PubMed...
  18. Weissenstein, U., Schneider, M.J., Pawlak, M., Cicenas, J., Eppenberger-Castori, S., Oroszlan, P., et al., 2006. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteom 6, 1427-1436. Go to original source... Go to PubMed...
  19. Wilson, R., Kavia, S., 2009. Comparison of large-core vacuum-assisted breast biopsy and excision systems. Recent Results Cancer Res. 173, 23-41. Go to original source... Go to PubMed...
  20. Yang, Z., Chevolot, Y., Ataman-Önal, Y., Choquet-Kastylevsky, G., Souteyrand, E., Laurenceau, E., 2012a. Cancer biomarkers detection using 3D microstructured protein chip: implementation of customized multiplex immunoassay. Sens. Actuators B: Chem. 175, 22-28. Go to original source...
  21. Yang, Z., Chevolot, Y., Gehin, T., Solassol, J., Mange, A., Souteyrand, E., Laurenceau, E., 2012b. Improvement of protein immobilization for the elaboration of tumourassociated antigen microarrays: application to the sensitive and specific detection of tumour markers from breast cancer sera. Biosens. Bioelectron. 40, 385-392. Go to original source... Go to PubMed...
  22. Yang, Z., Chevolot, Y., Gehin, T., Dugas, V., Xanthopoulos, N., Laporte, V., et al., 2013. Characterization of three amino-functionalized surfaces and evaluation of antibody immobilization for the multiplex detection of tumour markers involved in colorectal cancer. Langmuir 29, 1498-1509. Go to original source... Go to PubMed...